Dermal miconazole nitrate nanocrystals – formulation development, increased antifungal efficacy & skin penetration

• Published in: International journal of pharmaceutics Vol. 531; no. 1; pp. 350 - 359
• Main Authors: Pyo, Sung Min, Hespeler, David, Keck, Cornelia M., Müller, Rainer H.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.10.2017
• Subjects: Animals; Antifungal Agents - administration & dosage; Antifungal Agents - pharmacology; Candida albicans - drug effects; Chemistry, Pharmaceutical; Chlorhexidine digluconate; Dermal penetration; Drug Carriers - chemistry; Drug Compounding; Fungal skin infections; Inhibition zone assay; Miconazole - administration & dosage; Miconazole - pharmacology; Miconazole nitrate; Nanocrystals; Nanoparticles - chemistry; Skin; Skin Absorption; Swine; Tape stripping; Miconazole nitrate; Nanocrystals; Fungal skin infections; Tape stripping; Dermal penetration; Chlorhexidine digluconate; Inhibition zone assay
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2017.08.108

[Display omitted] Miconazole nitrate nanosuspension was developed to increase its antifungal activity and dermal penetration. In addition, the nanosuspension was combined with the synergistic additive chlorhexidine digluconate. The production was performed by wet bead milling and both production and formulation parameters were optimized. A stabilizer screening revealed poloxamer 407 and Tween 80 both at 0.15% as the most effective stabilizers for miconazole nanosuspensions at 1.0%. The nanocrystals were incorporated into a hydroxypropyl cellulose gel base. Short-term stability (3months) of the nanocrystal bulk population could be shown at room temperature and fridge. Besides the stable bulk nanocrystals, some longitudinal crystal growth to needle like crystals occurred. The addition of ionic compounds as the chlorhexidine digluconate often destabilizes suspensions. Surprisingly here, the addition minimized the crystal growth. An underlying mechanism is proposed. An inhibition zone assay was performed using Candida albicans (ATCC® 10231™). When comparing the nanocrystals in suspension and in gel to μm-sized miconazole nitrate formulations and two market products, the increase in inhibition zone diameter for the nanosuspension formulations was most pronounced in the chlorhexidine digluconate free formulations. These nanocrystal formulations were closely or similarly effective as the microsuspensions and the market products containing the synergistic chlorhexidine digluconate, showing the potential of the nanosuspension formulation. Nanosuspension performance was even further increased when chlorhexidine digluconate was added. Ex-vivo skin penetration studies on porcine ears revealed distinctly less remaining miconazole nitrate on the skin surface for nanocrystals (e.g., 76–86%) compared to market products (e.g. 94%). Also, penetration was increased e.g. in skin depth of 5–10μm from <1.0/1.7% to e.g. 3.3–6.2% for nanocrystals.